SAN FRANCISCO, CA – February 24, 2021 – Kalytera Therapeutics, Inc. (TSX VENTURE EXCHANGE: KLY and OTCQB: KALTF) (the “Company” or “Kalytera“) today provided the following corporate update at the request of the TSX Venture Exchange (“TSXV”) ahead of the reinstatement…
Continue Reading